News

BWXT Canada, Ltd. (“BWXT”), a subsidiary of BWX Technologies, Inc., and Westinghouse Electric Company announced today that they have signed a memorandum of understanding (MOU) to support nuclear new-build projects in Canada and globally. Under the agreement, BWXT has the potential to manufacture key AP1000® and AP300™ reactor components, including steam generators, reactor vessels, pressure vessels and heat exchangers.

BWX Technologies, Inc. reported third quarter 2024 results.

BWX Technologies, Inc. (NYSE: BWXT) today announced that its Nuclear Fuel Services, Inc. (NFS) subsidiary was selected by the U.S. Department of Energy (DOE) as one of the successful bidders for High-Assay Low-Enriched Uranium (HALEU) deconversion services to support the civil advanced reactor marketplace.

(LYNCHBURG, Va. – Sept. 3, 2024) – BWX Technologies, Inc. (NYSE: BWXT) announced today that Gary D. Camper has been appointed president of BWXT Nuclear Operations Group, Inc. (NOG) effective Sept. 1, 2024.

(LYNCHBURG, Va. – August 26, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract from the National Nuclear Security Administration (NNSA) to complete a yearlong engineering study to evaluate options for the deployment of a centrifuge pilot plant that would establish a domestic uranium enrichment capability for national security purposes.

BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business’ mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide.

LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1.

BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.

BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient.